Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease
Open accessThe DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
BACKGROUNDAn increase in intrahepatic triglyceride (IHTG) is the hallmark feature of nonalcoholic fatty liver disease (NAFLD) and is decreased by weight loss. Hepatic de novo lipogenesis (DNL) contributes to steatosis in individuals with NAFLD. The physiological factors that stimulate hepatic DNL and the effect of weight loss on hepatic DNL are not clear.METHODSHepatic DNL, 24-hour integrated plasma insulin and glucose concentrations, and both liver and whole-body insulin sensitivity were determined in individuals who were lean (n = 14), obese with normal IHTG content (n = 26), or obese with NAFLD (n = 27). Hepatic DNL was assessed using the deuterated water method corrected for the potential confounding contribution of adipose tissue DNL. Liver and whole-body insulin sensitivity was assessed using the hyperinsulinemic-euglycemic clamp procedure in conjunction with glucose tracer infusion. Six subjects in the obese-NAFLD group were also evaluated before and after a diet-induced weight loss of 10%.RESULTSThe contribution of hepatic DNL to IHTG-palmitate was 11%, 19%, and 38% in the lean, obese, and obese-NAFLD groups, respectively. Hepatic DNL was inversely correlated with hepatic and whole-body insulin sensitivity, but directly correlated with 24-hour plasma glucose and insulin concentrations. Weight loss decreased IHTG content, in conjunction with a decrease in hepatic DNL and 24-hour plasma glucose and insulin concentrations.CONCLUSIONSThese data suggest hepatic DNL is an important regulator of IHTG content and that increases in circulating glucose and insulin stimulate hepatic DNL in individuals with NAFLD. Weight loss decreased IHTG content, at least in part, by decreasing hepatic DNL.TRIAL REGISTRATIONClinicalTrials.gov NCT02706262.FUNDINGThis study was supported by NIH grants DK56341 (Nutrition Obesity Research Center), DK20579 (Diabetes Research Center), DK52574 (Digestive Disease Research Center), and RR024992 (Clinical and Translational Science Award), and by grants from the Academy of Nutrition and Dietetics Foundation, the College of Natural Resources of UCB, and the Pershing Square Foundation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Interestingly, DNL has been associated with hepatic and whole-body IR (glucose metabolism),24,25 suggesting that IR may accelerate hepatic DNL.25”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [25]
In the citing paper
“In a well-designed study by Smith et al. [50], the contribution of hepatic DNL to intrahepatic TG palmitate was 11%, 19%, and 38% in the lean, obese, and obese-MASLD groups, respectively.”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [50]
In the citing paper
“Hepatic DNL was inversely correlated with hepatic and whole-body insulin sensitivity, but directly correlated with 24-hour plasma glucose and insulin concentrations.”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [50]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Faul, F., Erdfelder, E., Lang, A.-G., & Buchner, A. (2007) · Behavior Research Methods · doi:10.3758/bf03193146 · Cited by 65,971
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
The metabolic phenotype in obesity: Fat mass, body fat distribution, and adipose tissue function
Goossens, G. H. (2017) · Obesity Facts · doi:10.1159/000471488 · Cited by 8,481
Antihyperlipidemic and Biochemical Activities of Mcy Protein in Streptozotocin Induced Diabetic Rats
Marella, S., Maddirela, D. R., Badri, K. R., Jyothi Kumar, M. V., & Chippada, A. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373954 · Cited by 5,938
Nonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604 · cited 5×
“First, the long (3-5 week) duration of D2O tracer administration in our study accounted for labelling of the liver TG pools that turn over slowly (12) and provided an integrated assessment of DNL during daily fasting and fed conditions over several weeks.”
BackgroundMethodResultInfluentialA new predictive equation for resting energy expenditure in healthy individuals
Mifflin, M., St Jeor, S., Hill, L., Scott, B., Daugherty, S., & Koh, Y. (1990) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/51.2.241 · Cited by 2,544 · cited 2×
“The initial daily energy content of the diet provided 75% of estimated energy requirements (54); subsequent meals and energy”
BackgroundMethodObesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications
Fabbrini, E., Sullivan, S., & Klein, S. (2010) · Hepatology · doi:10.1002/hep.23280 · Cited by 2,100
Self-citationNonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities
Sanyal, A. J., Campbell–Sargent, C., Mirshahi, F., Rizzo, W. B., Contos, M. J., Sterling, R. K., Luketic, V. A., Shiffman, M. L., & Clore, J. N. (2001) · Gastroenterology · doi:10.1053/gast.2001.23256 · Cited by 2,078
Molecular mediators of hepatic steatosis and liver injury
Browning, J. D., & Horton, J. D. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422422 · Cited by 1,772 · cited 1×
“Although the mechanism(s) responsible for the increase in hepatic DNL in people with NAFLD is not known, it is possible that increases in circulating insulin and glucose associated with hepatic and whole-body insulin resistance are involved in stimulating hepatic DNL because insulin and glucose activate SREBP-1c and C…”
Background
Research works printed but not linked: 2
- 10.1172/JCI22422 · DOI · Paper page
- 10.1016/S1097-2765(05)00010-9 · doi:10.1016/s1097-2765(05)00010-9 · Paper page
Cited by
Items 201–300 of 770
MetALD : New Perspectives on an Old Overlooked Disease
Ayares, G., Díaz, L. A., Idalsoaga, F. J., Alkhouri, N., Noureddin, M., Bataller, R. A., Loomba, R. S., Arab, J. P., & Arrese, M. A. (2025) · Liver International · doi:10.1111/liv.70017 · Cited by 40
Yadav, P., Khurana, A., Bhatti, J. S., Weiskirchen, R., & Navik, U. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106426 · Cited by 32
Karimkhanloo, H., Keenan, S. N., Bayliss, J. A., Nardo, W. D., Miotto, P. M., Devereux, C. J., Nie, S., Williamson, N. A., Ryan, A., Watt, M. J., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-32037-1 · Cited by 38
Mir, R., Jeelani, M., Alharthi, M. H., Rizvi, S. F., Sohail, S. K., Wani, J. I., Sabah, Z. U., BinAfif, W. F., Nandi, P. S., Alshahrani, A. M., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062770 · Cited by 53
“Fat accumulation and excess lipids increase mitochondria malfunction in obese individuals elevate ROS levels leading to metabolic dysfunction and excessive expression of pro-inflammatory markers [154,168].”
Zhang, Z., Yang, H., Han, F., & Guo, P. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47060464 · Cited by 43
“(2) Inhibition of fatty acid oxidation through various inflammatory signaling pathways, promoting lipid accumulation and worsening hepatic steatosis [86].”
InfluentialTargeted inhibition of hepatic de novo ceramide synthesis ameliorates MASH
Yu, X., Huang, C., Evers, M. J. W., Liu, J., Ting, H. J., Zhang, S., Chong, S. Y., Tan, M. S., Wang, S., Sayed, N., et al. (2025) · Science Advances · doi:10.1126/sciadv.adx2681 · Cited by 37
“In patients with MASLD, de novo lipogenesis has been reported to increase by three to five times ( 45 – 48 ).”
Valenzuela‐Vallejo, L., & Mantzoros, C. S. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155246 · Cited by 34
FMO2 ameliorates nonalcoholic fatty liver disease by suppressing ER-to-Golgi transport of SREBP1
Ke, C., Xiao, C., Li, J., Wu, X., Zhang, Y., Chen, Y., Sheng, S., Fu, Z., Wang, L., Ni, C., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000643 · Cited by 35
“[7] Inhibiting critical regulators responsible for DNL, including citrate/isocitrate carrier ATP-citrate lyase, acetyl-CoA carboxylase (ACC), and fatty acid synthase (FASN), represents an attractive therapeutic strategy for NAFLD, and some DNL inhibitors have reached the clinical research phase.”
Oligonucleotide therapies for nonalcoholic steatohepatitis
Li, S., Xiong, F., Zhang, S., Liu, J., Gao, G., Xie, J. H., & Wang, Y. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102184 · Cited by 35
“81 Mitochondrial FA b -oxidation may increase to adapt to the upregulated lipogenesis at an earlier stage, but decompensates to such changes, eventually leading to mitochondria damage, oxidative stress, and insulin signaling impairment.”
BackgroundHirano, T. (2025) · Journal of Diabetes Investigation · doi:10.1111/jdi.14398 · Cited by 44
“Microsomal TG transfer protein (MTP) plays a critical role in VLDL assembly by facilitating the lipidation of apoB with TG, and MTP activity is enhanced under insulin-resistant conditions 91 .”
GH directly inhibits steatosis and liver injury in a sex-dependent and IGF1-independent manner
Sarmento‐Cabral, A., del Río-Moreno, M., Vazquez-Borrego, M. C., Mahmood, M., Gutiérrez-Casado, E., Pelke, N., Guzman, G., Subbaiah, P. V., Córdoba‐Chacón, J., Yakar, S., et al. (2020) · Journal of Endocrinology · doi:10.1530/joe-20-0326 · Cited by 33
Lin, C., Adhikary, P., & Cheng, K. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.04.008 · Cited by 35
Nutritional, pharmacological, and environmental programming of NAFLD in early life
Galvan-Martinez, D. H., Bosquez-Mendoza, V. M., Ruíz‐Noa, Y., Ibarra‐Reynoso, L. D. R., Barbosa‐Sabanero, G., & Lazo-de-la-Vega-Monroy, M.-L. (2022) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00168.2022 · Cited by 32
Fu, X., Fletcher, J. A., Deja, S., Inigo-Vollmer, M., Burgess, S. C., & Browning, J. D. (2023) · Journal of Clinical Investigation · doi:10.1172/jci167442 · Cited by 30
“Tracer studies indicate that excess hepatic TG in NAFL originates from elevated de novo lipogenesis (DNL) (5–9) and the influx of non-esterified fatty acid (NEFA) released from insulin-resistant adipose tissue (10, 11).”
Liver insulinization as a driver of triglyceride dysmetabolism
Cook, J. R., Hawkins, M. A., & Pajvani, U. B. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00843-6 · Cited by 35
Puengel, T., & Tacke, F. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2374463 · Cited by 34
“Hepatic de novo lipogenesis plays a crucial role in the development of MASLD and progression to MASH [84,85].”
Potential therapeutic strategies for MASH: from preclinical to clinical development
Xie, Z., Li, Y., Cheng, L., Huang, Y., Rao, W., Shi, H., & Li, J. (2024) · Life Metabolism · doi:10.1093/lifemeta/loae029 · Cited by 33
Lee, H., Do, M. H., Jhun, H., Ha, S. K., Song, H.-S., Roh, S. W., Chung, W., Nam, Y., & Park, H. (2021) · Nutrients · doi:10.3390/nu13092989 · Cited by 35
“binding protein (ChREBP) and sterol regulatory element-binding protein 1 (SREBP-1), respectively, which activate genes associated with de novo lipogenesis [6,7].”
BackgroundZhang, X.-L., Wang, T.-Y., Targher, G., Byrne, C. D., & Zheng, M. (2022) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2022.0048 · Cited by 33
“In non-obese NAFLD individuals who consume a substantial amount of fructose; both carbohydrate responsive-element binding protein and sterol regulatory element binding protein 1c are indirectly activated by the high circulating levels of insulin and glucose associated with hepatic and whole-body IR, as well as the fru…”
BackgroundLi, H., Xi, Y., Liu, H., & Xin, X. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.914079 · Cited by 31
“Insulin resistance can promote hepatic lipid synthesis (36).”
BackgroundThe role of platelets in non-alcoholic fatty liver disease: From pathophysiology to therapeutics
Malladi, N., Alam, M. J., Maulik, S. K., & Banerjee, S. (2023) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2023.106766 · Cited by 34
Shankar, K., Metzger, N. P., Lawrence, C., Gupta, D., Osborne-Lawrence, S. L., Varshney, S., Singh, O., Richard, C. P., Zaykov, A. N., Rolfts, R., et al. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.101950 · Cited by 31
“Increased de novo lipogenesis, in fl ammation, and fi brosis are the hallmark features of MAFLD [43 e 45].”
Minetti, E. T., Hamburg, N. M., & Matsui, R. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1469492 · Cited by 38
MASLD, MASH, and the CKM Spectrum
Zannad, F. M., Khan, M. S., Bansal, N., Böhm, M., Francque, S., Girerd, N., Januzzi, J. L., Miller, V., Piché, M., Ratziu, V., et al. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.12.015 · Cited by 40
[Incisional hernia after surgery for abdominal aortic aneurysm].
Augestad, K. M., Wilsgaard, T., & Solberg, S. K. (2002) · Tidsskrift for Den Norske Laegeforening · Cited by 41
Establishment of a non‐alcoholic fatty liver disease model by high fat diet in adult zebrafish
Li, X., Zhou, L., Zheng, Y., He, T., Guo, H., Li, J., & Zhang, J. (2023) · Animal Models and Experimental Medicine · doi:10.1002/ame2.12309 · Cited by 33
“20-22 However, monitoring of rodents fed a high-fat diet involves high costs and time requirements, whereas the use of zebrafish allows for the rapid construction of an economical and effective model of NAFLD.”
Depression and NAFLD risk: A meta-analysis and Mendelian randomization study
Li, S., Li, S., Duan, F., & Lu, B. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.02.074 · Cited by 29
Metabolic Dysfunction-Associated Steatotic Liver Disease: Pathogenetic Links to Cardiovascular Risk
Ionescu, V., Gheorghe, G., Bacalbaşa, N., & Diaconu, C. C. (2025) · Biomolecules · doi:10.3390/biom15020163 · Cited by 37
“Elevated diacylglycerol levels lead to the translocation of protein kinase C ε (PKC ε ) to the plasma membrane, where it interacts with the kinase domain of the insulin receptor, thereby inhibiting the phosphorylation of insulin receptor substrate 2 (IRS-2) [112].”
Du, Z., Lin, L., Li, Y., Sun, M., Liang, Q., Sun, Z., & Duan, J. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.07.024 · Cited by 29
Adipose Tissue Biology and Effect of Weight Loss in Women With Lipedema
Cifarelli, V., Smith, G. I., González-Nieves, S., Samovski, D., Palacios, H. H., Yoshino, J., Stein, R. I., Fuchs, A. G., Wright, T. F., & Klein, S. (2024) · Diabetes · doi:10.2337/db24-0890 · Cited by 35
Self-citationThe pathogenesis of hepatic steatosis in MASLD: a lipid droplet perspective
Krahmer, N., Walther, T. C., & Farese, R. V. (2025) · Journal of Clinical Investigation · doi:10.1172/jci198334 · Cited by 35
“Under normal conditions, DNL contributes approximately 10% of hepatic FA input, but in obese and insulin-resistant states, this fraction may increase to approximately 40% (1).”
Histone acetyltransferase NAA40 modulates acetyl-CoA levels and lipid synthesis
Charidemou, E., Tsiarli, M. A., Theophanous, A., Yılmaz, V., Pitsouli, C., Strati, K., Griffin, J. L., & Kirmizis, A. (2022) · BMC Biology · doi:10.1186/s12915-021-01225-8 · Cited by 26
“zymes and metabolism would have important clinical implications, since DNL has been linked to insulin resistance and nonalcoholic fatty liver disease [16].”
BackgroundSimultaneous and Rapid Detection of Glucose and Insulin: Coupling Enzymatic and Aptamer-Based Assays
Nandhakumar, P., Djassemi, O., Raucci, A., Chang, A.-Y., Cheung, C., Dugas, Y., Silberman, J., Morales‐Fermin, S., Sandhu, S. S., Reynoso, M., et al. (2024) · Analytical Chemistry · doi:10.1021/acs.analchem.4c04289 · Cited by 26
Relationship between de novo lipogenesis and serum sex hormone binding globulin in humans
Simons, P. I. H. G., Valkenburg, O., Telgenkamp, I., van der Waaij, K. M., de Groot, D. M., Veeraiah, P., Bons, J. A. P., Taskinen, M., Borén, J., Schrauwen, P., et al. (2021) · Clinical Endocrinology · doi:10.1111/cen.14459 · Cited by 24
Rho-Kinase as a Therapeutic Target for Nonalcoholic Fatty Liver Diseases
Sousa‐Lima, I., Kim, H. J., Jones, J. G., & Kim, Y. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0197 · Cited by 28
“In addition, (2)H2O can be administered to humans on an outpatient basis under “real life” conditions [77] or to animals without disrupting their normal feeding routines [78].”
BackgroundGart, E., Salic, K., Morrison, M. C., Giera, M. A., Attema, J., de Ruiter, C., Caspers, M. P. M., Schuren, F. H. J., Bobeldijk‐Pastorova, I., Heer, M., et al. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.904740 · Cited by 26
“This is particularly relevant for the situation in NAFLD patients, in which it has also been demonstrated that hyperinsulinemia as a consequence of IR is a key driver of de novo lipogenesis (37).”
BackgroundBucarey, J. L., Paules, E. M., Trujillo‐Gonzalez, I., & Espinosa, A. (2024) · Antioxidants · doi:10.3390/antiox13111363 · Cited by 36
Nonalcohol fatty liver disease: balancing supply and utilization of triglycerides
Santos‐Báez, L. S., & Ginsberg, H. N. (2021) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000756 · Cited by 26
Deng, W., Fan, W., Tang, T., Wan, H., Zhao, S., Tan, Y., Agyare, O. K., Tan, J., Li, J., & Qu, S. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/3589525 · Cited by 29
“Moreover, NAFLD is associated with a high risk of multiorgan insulin resistance, type 2 diabetes, dyslipidemia, and coronary heart disease [5].”
Deprince, A., Hennuyer, N., Kooijman, S., Pronk, A. C. M., Baugé, E., Liénard, V., Verrijken, A., Dirinck, E. L., Vonghia, L., Woitrain, E., et al. (2022) · Hepatology · doi:10.1002/hep.32631 · Cited by 31
“Hepatic TG accumulation in insulin resistant individuals results from a combination of increased adipose tissue free fatty acid (FFA) release[5] and increased hepatic lipogenesis.[6,7] Importantly, these fluxes can be partially counterbalanced by enhanced hepatic TG output.”
BackgroundYoshino, M., Yoshino, J., Smith, G. I., Stein, R. I., Bittel, A. J., Bittel, D. C., Reeds, D. N., Sinacore, D. R., Cade, W. T., Patterson, B. W., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.08.012 · Cited by 28
Self-citationTănase, D. M., Gosav, E. M., Petrov, D., Jucan, A. E., Lăcătușu, C.-M., Floria, M., Tărniceriu, C. C., Costea, C. F., Ciocoiu, M., & Rezuș, C. (2021) · Diagnostics · doi:10.3390/diagnostics11112053 · Cited by 26
“Presently in the fast-food and sedentary lifestyle era, the rate of obesity has increased, which is one of the main conditions that can lead to NAFLD, insulin resistance (IR), type 2 diabetes (T2DM), and other metabolic disorders.”
BackgroundZhang, M., Ji, J., Lei, Y., Qin, F., Tao, Y., Li, N., Bian, J., Li, Z., Lai, M., & Qiu, Z. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107706 · Cited by 26
Spatial regulation of glucose and lipid metabolism by hepatic insulin signaling
He, B., Copps, K. D., Stöhr, O., Liu, B., Hu, S., Joshi, S., Haigis, M. C., White, M. F., Zhu, H., & Tao, R. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.03.015 · Cited by 31
Simons, P. I. H. G., Valkenburg, O., Bons, J. A. P., Stehouwer, C. D. A., & Brouwers, M. C. G. J. (2021) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.267 · Cited by 30
Subcutaneous Adipose Tissue Metabolic Function and Insulin Sensitivity in People With Obesity
Koh, H. E., van Vliet, S., Pietka, T., Meyer, G. A., Razani, B., Laforest, R. A., Gropler, R. J., & Mittendorfer, B. (2021) · Diabetes · doi:10.2337/db21-0160 · Cited by 25
Pathogenesis from Inflammation to Cancer in NASH-Derived HCC
Yu, S., Wang, J., Zheng, H., Wang, R., Johnson, N. L., Li, T., Li, P., Lin, J., Li, Y., Jin, Y., et al. (2022) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s377768 · Cited by 29
“tissues, followed by activation of macrophages and release of pro-inflammatory cytokines, such as tumor necrosis factor (TNF) -α and interleukin (IL)-6 inducing a chronic inflammation.(17,18) In turn, IR could also be secondary to a chronic”
BackgroundYu, S., Jiang, J., Li, Q., Liu, X., Wang, Z., Yang, L., & Ding, L. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.855008 · Cited by 24
“According to a previous study, NAFLD is characterized by excessive intrahepatic triglyceride (IHTG) content, which is universally associated with obesity and can lead to inflammation and fibrosis (Lu et al., 2018; Smith et al., 2020; Bril et al., 2020).”
BackgroundAflatounian, A., Paris, V. R., Richani, D., Edwards, M. C., Cochran, B. J., Ledger, W. L., Gilchrist, R. B., Bertoldo, M. J., Wu, L. E., & Walters, K. A. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101583 · Cited by 23
“Changes in hepatic lipid content during hyperinsulinemia are primarily due to increased de novo lipogenesis [62], and future work should aim to test whether the differences in hepatic lipid content observed here are indeed due to insulin-induced de novo lipogenesis.”
BackgroundThe Impact and Burden of Dietary Sugars on the Liver
Huneault, H. E., Tovar, A. R., Sanchez-Torres, C., Welsh, J. A., & Vos, M. B. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000297 · Cited by 31
“[62] 64] On the other hand, a study by Ter Horst et al revealed that patients with NAFLD and ce novo lipogenesis due to increased availability of lipogenic substrates like dietary fructose, while glucose-stimulated/ insulin action lipogenesis was attenuated.”
BackgroundOrganismal Fructose Metabolism in Health and Non-Alcoholic Fatty Liver Disease
Skenderian, S., Park, G. S. H., & Jang, C. (2020) · Biology · doi:10.3390/biology9110405 · Cited by 27
“In human patients with non-alcoholic steatohepatitis, hepatic lipogenesis accounts for up to 38% of liver palmitate [103].”
BackgroundIstfan, N., Hasson, B., Apovian, C., Meshulam, T., Yu, L., Anderson, W., & Corkey, B. E. (2021) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00094.2021 · Cited by 22
The Role of Epigenetic Control of Mitochondrial (Dys)Function in MASLD Onset and Progression
Caputo, V., Tarantino, G., Santini, S. J., Fracassi, G., & Balsano, C. (2023) · Nutrients · doi:10.3390/nu15224757 · Cited by 25
“Insulin-mediated stimulation of DNL, leading to an increased conversion of glucose to fatty acids, gains more and more importance as a regulator of intrahepatic triglyceride content in individuals with NAFLD [5].”
BackgroundA Review: Cytochrome P450 in Alcoholic and Non-Alcoholic Fatty Liver Disease
Jiang, Y., Cao, Y.-M., Cao, Y., Yan, T., Jia, C., & He, P. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s449494 · Cited by 25
Review article: Hepatic steatosis and its associations with acute and chronic liver diseases
Koenig, A. B., Tan, A., Abdelaal, H., Monge, F., Younossi, Z. M., & Goodman, Z. D. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.18059 · Cited by 30
“260,262 45 Structural studies suggest that the replacement of isoleucine by methionine at residue 148 may disrupt substrate binding by PNPLA3.”
BackgroundWan, X., Ma, J., Bai, H., Hu, X., Ma, Y., Zhao, M., Liu, J., & Duan, J. (2025) · Biomolecules · doi:10.3390/biom15010140 · Cited by 27
Bile acid signaling in MASLD: From pathogenesis to therapeutic applications
Simbrunner, B., Paternostro, R., Reiberger, T., & Trauner, M. (2025) · Hepatology · doi:10.1097/hep.0000000000001539 · Cited by 33
KHK, PNPLA3 and PPAR as Novel Targets for the Anti-Steatotic Action of Bempedoic Acid
Velázquez, A. M., Bentanachs, R., Sala‐Vila, A., Lázaro, I., Rodríguez-Morató, J., Sánchez, R. M., Laguna, J. C., Roglans, N., & Alegret, M. (2022) · Biomedicines · doi:10.3390/biomedicines10071517 · Cited by 23
“in NAFLD patients is high, reaching almost 40% [37].”
BackgroundLi, Y., Nie, J., Yang, Y., Li, J., Li, J., Wu, X., Liu, X., Chen, D., Yang, Z., Xu, F., et al. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c05889 · Cited by 22
The association between diabetes and obesity with Dengue infections
Sekaran, S. D., Liew, Z. M., Yam, H. C., & Raju, C. S. (2022) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-022-00870-5 · Cited by 27
“It is also said that the intermediary metabolic pathway of de novo lipogenesis is sensitive to insulin [108].”
BackgroundPapadopoulos, G., Legaki, A., Georgila, K., Vorkas, P. A., Giannousi, E., Stamatakis, G. M., Moustakas, I. I., Petrocheilou, M., Pyrina, I., Gercken, B., et al. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155552 · Cited by 26
Wang, S., Lin, X., Zhu, C., Dong, Y., Guo, Y., Xie, Z., He, X., Ju, W., & Chen, M. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1287916 · Cited by 24
Mahmoudi, S. K., Tarzemani, S., Aghajanzadeh, T., Kasravi, M., Hatami, B., Zali, M. R., & Baghaei, K. (2024) · European journal of medical research · doi:10.1186/s40001-024-01708-8 · Cited by 28
“Also, IR increases gluconeogenesis and diminishes hepatic glycogen synthesis, resulting in high glucose levels [77].”
BackgroundKakazu, E., Mino, M., & Kanto, T. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0048 · Cited by 28
Rodríguez-González, G. L., Vargas-Hernández, L., Reyes‐Castro, L. A., Ibáñez, C. A., Bautista, C. J., Lomas‐Soria, C., Itani, N., Estrada‐Gutiérrez, G., Espejel-Núñez, A., Pliego, A. F., et al. (2022) · Antioxidants · doi:10.3390/antiox11101871 · Cited by 25
“Three sources provide fatty acids to hepatic triglycerides: dietary fat, free fatty acids released from adipose tissue, and hepatic de novo lipogenesis [55]; the latter drives NAFLD in insulin resistance [56].”
BackgroundWestcott, F., Dearlove, D., & Hodson, L. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.117237 · Cited by 26
Pezzino, S., Sofia, M., Mazzone, C., Litrico, G., Greco, L. P., Gallo, L., Greca, G. L., & Latteri, S. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e35498 · Cited by 26
“De novo lipogenesis is widely recognized as a crucial element in the pathogenesis of NAFLD [210,211].”
BackgroundZhang, B., Zhang, C., Zhang, X., Li, N., Dong, Z., Sun, G., & Sun, X. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.8465 · Cited by 25
De novo lipogenesis in non‐alcoholic fatty liver disease: Quantification with stable isotope tracers
Belew, G. D., & Jones, J. G. (2022) · European Journal of Clinical Investigation · doi:10.1111/eci.13733 · Cited by 22
Weight loss in MASLD restores the balance of liver fatty acid sources
Lambert, J. E., Ramos-Roman, M. A., Valdez, M. J., Browning, J. D., Rogers, T., & Parks, E. J. (2025) · Journal of Clinical Investigation · doi:10.1172/jci174233 · Cited by 20
“DNL is a relatively flexible biochemical pathway, correlates with the magnitude of IHTG (25), is highly responsive to energy/carbohydrate restriction, and is reduced with improvement of insulin sensitivity (26–29).”
Advances in Adipose Tissue Biology
Corvera, S., Rajan, A., Townsend, K. L., Shamsi, F., Wu, J., Svensson, K. J., Zeltser, L. M., Collins, S., Reis, T., Tseng, Y., et al. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf032 · Cited by 28
Liu, J., Guan, L., Zhao, M., Li, Q., Song, A., Gao, L., Lin, H., & Zhao, J. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s316864 · Cited by 24
“Smith et al found that the increase in circulating glucose and insulin associated with IR promoted hepatic de novo lipogenesis (DNL) in NAFLD patients.(35) The carbohydrate-regulated adipogenic transcription factor ChREBP was increased in subjects with NAFLD and induced hepatic lipid accumulation.”
BackgroundAstarini, F. D., Ratnasari, N., & Wasityastuti, W. (2022) · Iranian Biomedical Journal · doi:10.52547/ibj.3647 · Cited by 26
“This condition causes insulin resistance that contributes to the development of NAFLD by increasing de novo lipogenesis in the liver and promoting lipolysis in other tissues, leading to a higher FFA supply to the liver [114] .”
BackgroundZhang, G.-H., Yuan, T.-H., Yue, Z., Wang, L., & Dou, G. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.1019899 · Cited by 23
“Impairment of glucose and lipid metabolic pathways, which is caused by the worldwide increase in the prevalence of obesity and type 2 diabetes mellitus (T2DM), is most likely behind the increase in people with NAFLD (Smith et al., 2020; Stefan and Cusi, 2022).”
BackgroundGuo, Y., Sun, Q., Wang, S., Zhang, M., Lei, Y., Wu, J., Wang, X., Hu, W., Meng, H., Li, Z., et al. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.117162 · Cited by 20
Marchianò, S., Biagioli, M., Roselli, R., Zampella, A., Giorgio, C. D., Bordoni, M., Bellini, R., Morretta, E., Monti, M. C., Distrutti, E., et al. (2021) · The FASEB Journal · doi:10.1096/fj.202101397r · Cited by 22
Obesity and Exercise: New Insights and Perspectives
James, N. M., & Stanford, K. I. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf017 · Cited by 20
Ma, L., Song, H., Zhang, C., & Hou, D. (2023) · Biomolecules · doi:10.3390/biom14010034 · Cited by 21
Dietary protein intake and obesity-associated cardiometabolic function
Fappi, A., & Mittendorfer, B. (2020) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000689 · Cited by 28
“NAFLD is a common complication of obesity and is tightly linked to insulin resistance [44,45].”
BackgroundHepatic Mediators of Lipid Metabolism and Ketogenesis: Focus on Fatty Liver and Diabetes
Fernandes, G. W., & Bocco, B. M. L. C. (2020) · Current Diabetes Reviews · doi:10.2174/1573399816999201103141216 · Cited by 20
Manka, P. P., Kaya, E., Canbay, A. E., & Syn, W. (2021) · Digestive Diseases and Sciences · doi:10.1007/s10620-021-07206-9 · Cited by 24
Su, M., Cao, D., Wang, Z., Duan, Y., & Huang, Y. P. (2021) · Biomedicines · doi:10.3390/biomedicines10010005 · Cited by 21
“For example, dietary carbohydrates can be converted to fatty acids in hepatocytes via de novo lipogenesis (DNL) to produce triglycerides (TGs) [9].”
BackgroundTan, X., Sun, Y. E., Chen, L., Hu, J., Meng, Y., Yuan, M., Wang, Q., Li, S., Zheng, G., & Qiu, Z. (2022) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.2c01013 · Cited by 20
SGLT-2 Inhibitors for Non-Alcoholic Fatty Liver Disease: A Review
Xu, R., Lian, D., Xie, Y., Chen, Z., Wang, Y., Mu, L., Wang, Y., & Zhang, B. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2807134 · Cited by 25
“Research has suggested that IR drives hepatic de novo lipogenesis (DNL) in patients with NAFLD [16].”
BackgroundMi, A., Hu, Q., Liu, Y., Zhao, Y., Shen, F., Lan, J., Lv, K., Wang, B., Gao, R., & Yu, X. (2023) · Food & Function · doi:10.1039/d3fo03572g · Cited by 21
García, S. G., Rondinella, D., Ponziani, F. R., Miele, L., Gasbarrini, A., Cammarota, G., Lanas, Á., & Gomollón, F. (2024) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2024.101924 · Cited by 21
Huang, W., Wang, H., Shen, Z., Wang, X., & Yu, X. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1448359 · Cited by 21
“Insulin resistance improves the plasma levels of insulin and glucose, further promoting DNL. DNL may produce toxic metabolites, such as ceramides, which can exacerbate IR (40, 41).”
BackgroundAssociation between Mediterranean Diet and Fatty Liver in Women with Overweight and Obesity
Leone, A., Bertoli, S., Bedogni, G., Vignati, L., Pellizzari, M., & Battezzati, A. (2022) · Nutrients · doi:10.3390/nu14183771 · Cited by 20
“Peripheral insulin resistance also enhances hepatic de novo lipogenesis [45,46], increasing hepatic triglyceride accumulation.”
BackgroundImpact of Remnant Cholesterol on Cardiovascular Risk in Diabetes
Elías-López, D., Wadström, B. N., Vedel‐Krogh, S., Kobylecki, C. J., & Nordestgaard, B. G. (2024) · Current Diabetes Reports · doi:10.1007/s11892-024-01555-1 · Cited by 18
Pathogenesis of metabolic dysfunction-associated steatotic liver disease and donor liver damage
Gou, C., Zhang, W., Xu, H., Zhang, H., Ding, R., & Zhang, X. (2025) · iLiver · doi:10.1016/j.iliver.2025.100195 · Cited by 27
“…promotes MASLD is the development of hyperglycemia and compensatory hyperinsulinemia, increased breakdown of peripheral lipid particles (chylomicrons and low-density lipoproteins), and increased FFA concentrations, leading to increased hepatic DNL. 16,47 MASLD also promotes insulin resistance.”
Alshehade, S. A., Zarzour, R. H. A., Murugaiyah, V., Lim, S. Y. M., El-Refae, H. G., & Alshawsh, M. A. (2022) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2022.09.001 · Cited by 21
Nutritional regulation of hepatic de novo lipogenesis in humans
Cross, E., Dearlove, D., & Hodson, L. (2023) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000914 · Cited by 23
“Indeed, in individuals with a larger IHTG pool, it is suggested that a labelling period of more than 10days is required to achieve a more accurate estimation of hepatic DNL [13 && ].”
BackgroundInfluentialCho, Y. K., Kim, M., Kim, Y., Jung, C. H., Lee, W. J., & Park, J. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1163052 · Cited by 20
“Hormone-sensitive lipase is no longer properly controlled by insulin within adipocytes, resulting in increased lipolysis of adipocyte triglycerides and levels of free fatty acids in the circulation (38), and then, insulin resistance exacerbates the predisposition for increased liver fat accumulation (39).”
BackgroundGut microbiota and metabolite interface-mediated hepatic inflammation
Yang, M. J., Massad, K., Kimchi, E. T., Staveley-O’Carroll, K. F., & Li, G. (2024) · Immunometabolism · doi:10.1097/in9.0000000000000037 · Cited by 20
“Insulin resistance increases the circulating levels of glucose and drives hepatic de novo lipogenesis to aggregate NAFLD progression [70] .”
BackgroundPoli, S., Emara, A. F., Lange, N. F., Ballabani, E., Buser, A., Schiavon, M., Herzig, D., Man, C. D., Bally, L., & Kreis, R. (2024) · NMR in Biomedicine · doi:10.1002/nbm.5123 · Cited by 17
“Following the recommendation of De Feyter et al., 32 [6,6'- 2 H 2 ]-Glc was preferred over singly deuterated [1-2 H]-Glc for the double content of deuterium nuclei and over perdeuterated [1,2,3,4,5,6,6 0 ,- 2 H 7 ]-Glc due to lower costs and ease of interpretation.”
Gonzalez, J. T. (2024) · European Journal of Nutrition · doi:10.1007/s00394-024-03365-3 · Cited by 25
“De novo lipogenesis is an important process in the regulation of hepatic lipid content and atherogenic lipoprotein production [52].”
BackgroundZhou, Q., Hu, H., Hu, L., Liu, S., Chen, J., & Tong, S. (2024) · Journal of Global Health · doi:10.7189/jogh.14.04060 · Cited by 20
“Furthermore, saturated fat intake also causes insulin resistance [33], which may play a role in the pathophysiology of NAFLD by stimulating hepatic de novo lipogenesis and contributing to hepatic steatosis [35].”
BackgroundWang, H., Shan, C., Guo, G., Ning, D., & Miao, F. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113025 · Cited by 24
Targeting acetyl-CoA carboxylases for the treatment of MASLD
Mateo-Marín, M. A., & Alves‐Bezerra, M. (2024) · Journal of Lipid Research · doi:10.1016/j.jlr.2024.100676 · Cited by 28
Dobbie, L. J., Kassab, M., Davison, A., Grace, P., Cuthbertson, D. J., & Hydes, T. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10245755 · Cited by 18
“High levels of circulating glucose and insulin increase rates of hepatic de novo lipogenesis leading to high levels of free fatty acids (FFA) in the liver; excess FFAs are stored as intrahepatic triglycerides [37].”
Background
Metadata
- Authors
- Smith, G. I., Shankaran, M., Yoshino, M., Schweitzer, G. G., Chondronikola, M., Beals, J. W., Okunade, A. L., Patterson, B. W., Nyangau, E., Field, T., Sirlin, C. B., Talukdar, S., Hellerstein, M. K., & Klein, S.
- Affiliations
- Washington University in St. Louis (US)
- University of California, Berkeley (US)
- University of California San Diego (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Corresponding author
- Klein, Samuel
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2020-02-04
- Volume
- 130
- Issue
- 3
- Pages
- 1453-1460
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC7269561
- OpenAlex
- W2993862932
- Cited by
- 771
- References
- 65
- Citations by year
- 2026: 121 · 2025: 136 · 2024: 153 · 2023: 123 · 2022: 104 · 2021: 92 · 2020: 40
- FWCI
- 44.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health (DK56341,DK20579,DK52574,RR024992)
- College of Natural Resources, University of California at Berkeley (N/A)
- Pershing Square Foundation (N/A)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- non-alcoholic fatty liver disease, hepatic de novo lipogenesis, insulin resistance, intrahepatic triglyceride, hepatic insulin sensitivity, weight loss, obesity, hepatic steatosis, plasma glucose, hyperinsulinemic-euglycemic clamp
- MeSH terms
- Adult, Blood Glucose, Female, Humans, Insulin, Insulin Resistance, Liver, Male, Triglycerides, Palmitic Acid, Lipogenesis, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.